Compare IOSP & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | NRIX |
|---|---|---|
| Founded | 1938 | 2009 |
| Country | United States | United States |
| Employees | N/A | 357 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 1998 | 2020 |
| Metric | IOSP | NRIX |
|---|---|---|
| Price | $95.68 | $25.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $93.00 | $30.50 |
| AVG Volume (30 Days) | 133.0K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 228.87 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $1,778,000,000.00 | $76,987,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.10 | $48.05 |
| P/E Ratio | $37.47 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $65.51 | $8.20 |
| 52 Week High | $96.68 | $28.23 |
| Indicator | IOSP | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 50.27 |
| Support Level | $91.70 | $24.61 |
| Resistance Level | $96.41 | $28.23 |
| Average True Range (ATR) | 2.06 | 1.02 |
| MACD | -0.25 | -0.12 |
| Stochastic Oscillator | 57.68 | 49.72 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.